28860-96-0 Usage
Description
DL-3-(3,4-Dimethoxyphenyl)-2-methyl-2-hydrazine propionic acid, also known as (αS)-α-Hydrazinyl-3,4-dimethoxy-α-methyl-benzenepropanoic Acid, is an organic compound that serves as a crucial intermediate in the pharmaceutical industry. It is characterized by its unique molecular structure, which includes a hydrazine group and a dimethoxyphenyl moiety, contributing to its reactivity and potential applications in drug synthesis.
Uses
Used in Pharmaceutical Synthesis:
DL-3-(3,4-Dimethoxyphenyl)-2-methyl-2-hydrazine propionic acid is used as an intermediate in the synthesis of (S)-(-)-Carbidopa (C175985), a peripheral decarboxylase inhibitor. DL-3-(3,4-Dimethoxyphenyl)-2-methyl-2-hydrazine propionic acid plays a significant role in the treatment of Parkinsonism, as it is commonly used in combination with L-DOPA (D533751) to enhance the therapeutic effects and reduce side effects associated with the treatment.
The use of DL-3-(3,4-Dimethoxyphenyl)-2-methyl-2-hydrazine propionic acid in the synthesis of (S)-(-)-Carbidopa is due to its ability to provide a stable and efficient route for the production of the final drug product. This intermediate is essential for the development of effective treatments for Parkinson's disease, a neurodegenerative disorder that affects millions of people worldwide.
Check Digit Verification of cas no
The CAS Registry Mumber 28860-96-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,8,6 and 0 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 28860-96:
(7*2)+(6*8)+(5*8)+(4*6)+(3*0)+(2*9)+(1*6)=150
150 % 10 = 0
So 28860-96-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H18N2O4/c1-12(14-13,11(15)16)7-8-4-5-9(17-2)10(6-8)18-3/h4-6,14H,7,13H2,1-3H3,(H,15,16)
28860-96-0Relevant articles and documents
CARBIDOPA PRODRUGS AND USES THEREOF
-
Page 71, (2010/02/07)
Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.
